If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
Learn more: RNA editing study shows potential for more effective precision cancer treatment
The Latest on: Precision cancer medicine
[google_news title=”” keyword=”precision cancer medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Precision cancer medicine
- Novant Health deploys high-tech robotics for lung cancer treatmenton May 9, 2024 at 4:49 am
Novant Health now has access to high-tech robotics equipment at its Agnes B. and Edward I. Weisiger Cancer Institute. That will improve diagnostics and treatment for lung cancer patients.
- UQ's AMTAR hub advances the development of hyper-accurate cancer drugson May 7, 2024 at 9:01 pm
The Australian Research Council (ARC) hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) is a one-stop-shop connecting biotech firms with expertise and equipment to design, test and ...
- UAE: Breast Cancer Prevention, Precision Medicine To Be Advanced By New Partnershipon May 6, 2024 at 12:35 pm
Breast cancer is the most common cancer among women worldwide. According to the Ministry of Health and Prevention (MoHAP), it is the leading cause of cancer death, resulting in 11.6 per cent of all ...
- M42, AstraZeneca sign agreement to advance prevention and precision medicine for breast canceron May 5, 2024 at 5:00 pm
Peter Raouf, GCC Oncology Business Unit Director at AstraZeneca, said, “This collaboration with M42 represents a significant step forward in our commitment to advancing personalised precision medicine ...
- Sweden eyes broader use of precision cancer medicineon May 3, 2024 at 11:49 am
Swedish researchers are preparing a national clinical trial with the aim to personalise off-label cancer drugs for patients who have run out of treatment options. The trial hopes to lead to a broad ...
- How the advancement in precision medicine is promising new hopes in breast cancer treatmenton April 30, 2024 at 8:13 pm
Breast cancer remains one of the most prevalent and deadly cancers affecting women worldwide. While traditional treatment approaches such as chemotherapy, surgery, and radiation therapy have been ...
- Precision medicine and how it will help with cancer treatments, rising costson April 28, 2024 at 8:55 pm
The approach dovetails perfectly with Singapore’s emerging focus on preventive health. Read more at straitstimes.com.
- Cancer patients can now be 'matched' to best treatment with DNA and lab-dish experimentson April 13, 2024 at 5:00 pm
To solve this problem, doctors analyze DNA mutations in the patient's tumor, blood or saliva to match cancer medicines to patients. This approach is called precision medicine. However, the ...
- Personalized cancer treatments based on testing drugs quickly leads to faster treatment, better outcomeson April 10, 2024 at 5:00 pm
To solve this problem, doctors analyze DNA mutations in the patient's tumor, blood or saliva to match cancer medicines to patients. This approach is called precision medicine. However, the ...
via Bing News